- Open
- 172.60
- High
- 173.90
- Low
- 160.60
- Close
- 162.00
- Change
- -14.50 (-8.23%)
- Volume
- 1,383,528
| 25 Aug 2026 | 07:00:03 | Appointment of CDPO |
| 20 Aug 2026 | 17:30:01 | LTIP awards; Director/PDMR Notification |
| 19 Aug 2026 | 07:00:03 | Interim results for the 6 months ended 30 June 26 |
| 12 Aug 2026 | 16:30:00 | Share Incentive Plan - Director/PDMR Shareholding |
| 3 Aug 2026 | 17:00:01 | Issue of Equity and Total Voting Rights |
| 1 May 2026 | Oxford Nanopore Technologies plc Accounts 31-12-2025 | |
| 30 Apr 2025 | Oxford Nanopore Technologies plc Accounts 31-12-2024 | |
| 7 Jun 2024 | Annual Report and Accounts 2023 |
Oxford Nanopore Technologies plc develops and commercializes a novel nanopore-based sensing platform for DNA and RNA analysis. The company offers rapid, accessible, and affordable sequencing solutions primarily for research, clinical, and biopharmaceutical applications. Its technology is utilized by researchers, healthcare providers, and industrial customers, enabling insights in areas such as infectious disease, oncology, and synthetic biology. Oxford Nanopore operates globally, focusing on expanding its presence in both research and applied markets.
Lord Spencer of Alresford has interests in this issuer
| 25 Aug 2026 | 07:00:03 | Appointment of CDPO |
| 20 Aug 2026 | 17:30:01 | LTIP awards; Director/PDMR Notification |
| 19 Aug 2026 | 07:00:03 | Interim results for the 6 months ended 30 June 26 |
| 12 Aug 2026 | 16:30:00 | Share Incentive Plan - Director/PDMR Shareholding |
| 3 Aug 2026 | 17:00:01 | Issue of Equity and Total Voting Rights |
| 1 May 2026 | Oxford Nanopore Technologies plc Accounts 31-12-2025 | |
| 30 Apr 2025 | Oxford Nanopore Technologies plc Accounts 31-12-2024 | |
| 7 Jun 2024 | Annual Report and Accounts 2023 |
Oxford Nanopore Technologies plc develops and commercializes a novel nanopore-based sensing platform for DNA and RNA analysis. The company offers rapid, accessible, and affordable sequencing solutions primarily for research, clinical, and biopharmaceutical applications. Its technology is utilized by researchers, healthcare providers, and industrial customers, enabling insights in areas such as infectious disease, oncology, and synthetic biology. Oxford Nanopore operates globally, focusing on expanding its presence in both research and applied markets.
Lord Spencer of Alresford has interests in this issuer
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £81.36bn | +0.3% | |
ONTOxford Nanopore Technologies plc | £1.58bn | -0.1% |
| £128m | +0.0% | |
| £36m | +0.6% | |
| £24m | -0.3% | |
| £5m | -0.5% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £81.36bn | +0.3% | |
ONTOxford Nanopore Technologies plc | £1.58bn | -0.1% |
| £128m | +0.0% | |
| £36m | +0.6% | |
| £24m | -0.3% | |
| £5m | -0.5% |
